

PROF. HUMAID OBAID ALSHAMSI
MD (HON), FRCP(LONDON), FRCP(CANADA), FRCPI,
FRCP(GLASGOW), FRCP(EDINBURGH), FACP(USA)
Canadian Board Certified in Internal Medicine and Medical Oncology

Professor Humaid Obaid Al-Shamsi serves as Chief Executive Officer of Burjeel Cancer Institute in Abu Dhabi, UAE. He is President of the Emirates Oncology Society and holds a leadership role in the Gulf Cancer Society. He is Visiting Professor at Harvard Medical School at Harvard University and Visiting Scientist at Dana-Farber Cancer Institute, Full Professor of Oncology at the Ras Al Khaimah Medical and Health Sciences University in Ras Al Khaimah, UAE. An Adjunct Professor of Oncology at the College of Medicine, University of Sharjah, and Honorary Professor at Gulf Medical University in Ajman, UAE.

He graduated with honors from University College Cork, Ireland, in 2004. He completed his residency in internal medicine at McMaster University, Canada, followed by a fellowship in medical oncology and advanced training in gastrointestinal (GI) oncology and palliative care. He is the first Emirati to complete a fellowship in palliative care in the UAE. During his training at McMaster University, he received multiple awards, including the Outstanding Senior Resident of the Year Award by the Medical staff Association of McMaster University (2012) and the Jeff Ginsberg Subspecialty Resident Award (2012).

Professor Al-Shamsi is the first Emirati to be promoted to the rank of Professor in Oncology in the UAE. He serves as Chairman for Colorectal Cancer in the MENA region, appointed by the National Comprehensive Cancer Network® (NCCN) in the USA. He is the only member of the Lung Cancer Policy Network in the MENA region, which aims to advance lung cancer research and screening globally. He is Chairman of the Oncology and Hematology Fellowship Training Program for the National Institute for Health Specialties in the United Arab Emirates. He is the only member in the GCC of the WIN Consortium, an international organization representing all stakeholders in personalized cancer medicine worldwide.

He is board-certified in both internal medicine and oncology by the UK, USA (ABIM), and Canada (FRCPC). He is the only physician in the UAE with a subspecialty fellowship certification and training in gastrointestinal oncology and the first Emirati to train and complete a clinical post-doctoral fellowship in palliative care. He is the first physician globally to be documented as having been granted the well-recognized royal fellowships from the royal colleges of FRCP (Canada), FRCP (Ireland), FRCP (London), FRCP (Edinburgh), FRCP (Glasgow), and the American College of Physicians, FACP (USA), reflecting broad international recognition of his clinical and academic standing.

From 2014 to 2017, he served as Assistant Professor at the University of Texas MD Anderson Cancer Center. He was the first (inaugural) graduate of the Sheikh Khalifa Bin Zayed Program for outstanding UAE Physicians training in 2016 — a prestigious national scholarship/training initiative. He has authored more than 200 peer-reviewed articles published in leading journals

including CA: A Cancer Journal for Clinicians, Cancer, JAMA Oncology, Lancet Oncology, Journal of Clinical Oncology, The Oncologist, BMC Cancer, and many others. He received the Publication of the Year 2020 award from The Oncologist journal for an international paper on COVID-19 and cancer management. He is a regular peer reviewer for numerous international oncology journals and has served as guest editor for several leading oncology publications. He is also involved in the Global Burden of Disease (GBD) research network, contributing to large-scale analyses that inform cancer epidemiology and health policy worldwide, and is a regular contributor to the American Society of Clinical Oncology (ASCO) Connection platform, where he shares insights on oncology practice, system development, and global cancer care. He also chairs sessions at major international congresses (e.g., ESMO Congress 2025). His areas of expertise include precision oncology and cancer care in the UAE. In 2016, he co-authored with his MD Anderson colleagues a landmark study in the Journal of Clinical Oncology that described a new distinct subgroup of colorectal cancer: non-V600 BRAF-mutated colorectal cancer.

In 2022, Professor Al-Shamsi published the first book on cancer research in the UAE and the first book on cancer in the Arab world, both launched at Dubai Expo 2020. *Cancer in the Arab World* has been downloaded more than 600,000 times in its first two years and remains the ultimate source of cancer data in the Arab region. He also published the first comprehensive book *Cancer Care in the United Arab Emirates*, the first book in UAE history to document cancer care in the country, addressing many topics for the first time. In addition, he authored the open-access book *Healthcare in the United Arab Emirates*. This book achieved over 100,000 downloads in its first two months. All of his books have been made open access to ensure free access to scientific knowledge for everyone. His cancer research focuses on precision oncology and multi-omics AI-driven biomarker discovery in cancer.

Professor Al-Shamsi is passionate about advancing cancer care across the UAE and the GCC region. As President of the Emirates Oncology Society and through his leadership role in the Gulf Cancer Society, he has helped build one of the most active oncology education platforms in the MENA region, offering frequent, high-quality educational activities accessible to oncologists across the region. He has been instrumental in bringing major international oncology educational initiatives to the UAE and the MENA region, including Best of ESMO, ESMO Breast, and Best of ASCO. He has made significant contributions to cancer awareness and early detection through public education on social media platforms and has championed free consultations for cancer patients without insurance, ensuring no patient is denied timely expert guidance due to financial barriers. He is recognized as the most followed oncologist in the world, with over one million subscribers across Instagram, Twitter (X), LinkedIn, and TikTok. In 2022, he received the prestigious Feigenbaum Leadership Excellence Award from Sheikh Hamdan Smart University for his exceptional leadership and research contributions. He was also awarded the Sharjah Award for Volunteering in recognition of providing thousands of free consultations to cancer patients across the UAE and the MENA region. He was named Researcher of the Year in the UAE in both 2020 and 2021 by the Emirates Oncology Society.

In May 2024, His Highness Sheikh Mansour bin Zayed Al Nahyan, Vice President of the United Arab Emirates, awarded him first place in the Emirati Talent Competitiveness Council (NAFIS)

program for outstanding leadership in the private sector across all business and medical disciplines. He was recognized as one of The 100 Most Influential CEOs in Oncology in 2025. In February 2025, he was awarded the Sheikha Fatima bint Mubarak Program for Excellence and Community Intelligence Award by the UAE President in recognition of his role as a successful role model in UAE society for increasing cancer awareness across the UAE and GCC. In October 2025, he was officially received by His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, in recognition of his academic achievements (Harvard Visiting Professor and Dana-Farber appointments) as the first GCC national to achieve this academic ranking.

As CEO of Burjeel Cancer Institute, Professor Al-Shamsi leads the largest cancer network in the UAE, comprising more than 30 oncologists and hematologists. Despite his extensive leadership, academic, and administrative responsibilities, he remains in full clinical practice, conducting clinics five days a week to continue providing direct, high-quality care to his patients.

Under his leadership, the institute has built one of the country's first comprehensive adult and pediatric bone marrow transplant programs and secured the UAE's first European Society for Medical Oncology (ESMO) accreditation for a cancer center. In addition to his clinical and administrative responsibilities, he is actively engaged in education and research training for medical trainees at all levels to enhance their clinical and research skills. He has shaped the future oncology workforce of the UAE by establishing the country's first hematology and oncology fellowship training pathway and currently serves as Chairman of the Hematology and Oncology Fellowship Program, accredited by the UAE National Institute for Health Specialties at Burjeel Cancer Institute.

Professor Al-Shamsi's leadership has profoundly shaped the UAE oncology landscape. He has been a key architect behind several landmark national initiatives that have transformed cancer care delivery in the country. These include major contributions to the development of advanced national oncology care standards in collaboration with health authorities, the launch of the UAE's National Guideline for Lung Cancer Screening and Diagnosis—which established a unified, evidence-based framework for early detection and risk stratification—and the establishment of the National Multidisciplinary Committee for Cancer Case Assessment through Ministerial Decree No. (20) of 2025, which formalizes multidisciplinary decision-making at a national level. In addition, he holds governmental advisory roles, including Advisor and Member of Governmental Committees for the Department of Health – Abu Dhabi, Dubai Health Authority, Ministry of Health & Prevention, and has been a Member of the Steering Committee on National Cancer Control Indicators since January 2018.

His mission is to advance cancer care in the UAE and the MENA region and to make high-quality cancer care accessible to everyone in need around the globe.

CURRENT APPOINTMENTS & CLINICAL EXPERIENCE

- **Chief Executive Officer**
Burjeel Cancer Institute – Burjeel Medical City – Burjeel Holding – Abu Dhabi
Jul 2024 – Current
- **Director of the Oncology Services Burjeel Holding – GCC**
Burjeel Cancer Institute – Burjeel Holding – Abu Dhabi
Jan 2023- Jul 2024
Working to establish Burjeel oncology network in GCC, Oman has been established and now working to establish Saudi
- **Director of the Oncology Services Burjeel Holdings & Consultant Medical Oncologist**
Oct 2020 – Jan 2023
Burjeel Cancer Institute – Burjeel Holding – Abu Dhabi, UAE
Established the most comprehensive cancer network in the UAE with 7 locations in Abu Dhabi, Dubai, Al Ain and Sharjah. Overseeing 17 medical oncologists, radiation oncologists, and hematologists. Established the most comprehensive bone marrow transplant unit in the UAE for adult and pediatric.

ACADEMIC APPOINTMENTS

- **Professor (Visiting)**
Harvard Medical School (HMS)
Harvard University
Boston, USA
Jan 2025 – Current
- **Visiting Scientist**
Dana Farber Cancer Institute
Harvard University
Boston, USA
Jan 2025 – Current
- **Professor (Full)**
Ras Al Khaimah Medical Health and Science University
Ras Al Khaimah – UAE
Jun 2024 – Current
- **Professor (Adjunct)**
College of Medicine
University of Sharjah
Sharjah- UAE
Mar 2021 – Current, renewed May 2023
- **Professor (Honorary)**
College of Medicine

**Gulf Medical University
Ajman – UAE
June 2025- ongoing**

BOARD CERTIFICATIONS

- **Canadian Board in Medical oncology - Medical Oncology specialist certification -The Royal College of Physicians and Surgeons of Canada – FRCP(C) Medical oncology
Nov-2012**
- **American Board in Medical Oncology (ABIM)
Dec-2012**
- **Membership Royal College of Physician of United Kingdom – Specialist Certification Examination in Medical Oncology – MRCP (UK) Medical Oncology
Oct-2012**
- **Canadian Board in Internal Medicine, Royal College of Physicians and Surgeons of Canada Specialty exam – FRCP(C) Internal Medicine
Jun-2011**
- **American Board in Internal Medicine – ABIM Board Certified
Aug-2010
Scored at the Top 10%**
- **National Board of Physicians and Surgeons, USA
Board Certified in Internal Medicine and Medical Oncology
August 11, 2025**

FELLOWSHIP

- **Fellow of the Royal College of Physicians of Ireland
April 9th 2026
RCP # 19243685**
- **Fellow of the Royal College of Physicians of Edinburgh
February 2025
RCPE # 884699**
- **Fellow of the Royal College of Physicians and Surgeons of Glasgow
February 21st 2024
RCPSG # 179812**
- **Fellow of the Royal College of Physicians London, UK
Oct 2023
RCP # 171754**
- **Fellow American College of Physicians**

Nov 2013 – Present
01379227

- **Fellow of the Royal College of Physicians and Surgeons of Canada**
Jul 2011- Present
999297

CURRENT PROFESSIONAL ASSOCIATION

- **President of the Emirates Oncology Society (EOS) www.EOS.ae**
Nov 2018 – Current
<https://eos-uae.com/>
- **Chairman of UAE oncology and hematology fellowship training program**
National Institute Health Specialty
May 2022 - Current
- **Member of the UAE National Committee**
Current
- **Society Chair of the Gulf Cancer Society**
Current
<https://gulfcancersociety.com/>
- **Chairman of Colon Cancer Guideline Committee- MENA- NCCN**
Dec 2021 - Current
- **President of the Gulf Oncology Society (EOS)**
Dec 2021 – July 2025
- **Member of Lung Cancer Policy Network**
Current
<https://www.lungcancerpolicynetwork.com/members/humaid-al-shamsi/>

PREVIOUS APPOINTMENTS & CLINICAL EXPERIENCE

- **Consultant Medical Oncologist – Head of Medical Oncology Department**
Jul 9th, 2017 – Dec 31st, 2021
AL Zahra Hospital – Dubai
Dubai – UAE
- **Associate professor (Adjunct)**
College of Medicine
Mar 2017 – Apr 2021
University of Sharjah – Sharjah – UAE
- **Assistant professor (Full time) - Consultant Medical Oncologist**
Jun 2014 – Dec 2016

Department of Gastrointestinal Medical Oncology
MD Anderson Cancer Center
 University of Texas – Houston – United States

- **Assistant professor (Adjunct)**
Oct 2013 – Jun 2016
Department of Medical Oncology
 Juravinski Cancer Center
 McMaster University – Hamilton – Canada

POSTGRADUATE EDUCATION

(RESIDENCY & FELLOWSHIP)

- **Combined Post-Doctoral advanced Clinical fellowship in Gastrointestinal Oncology and Palliative Oncology**
 Jul 2012 – Sep 2013 McMaster University
- **Medical Oncology Fellowship Training Program**
 Jul 2010 - Jun 2012 McMaster University
- **Internal Medicine Training Program**
 Jul 2007 - Jun 2010 McMaster University

UNDERGRADUATE EDUCATION

- 1998- Jun 2004 University College Cork Medical School, Cork, Ireland
BMedSc (Hon), Completed June 2002, awarded June 2004
MB(Hon), BAO, Bch June 2004 ~ Graduation with Honours

SCHOLARSHIPS

- **The First graduate of the Sheikh Khalifa distinguished physician scholarship program 2012-2014**
A UAE national and highly specialized program to train distinguished UAE physicians at a world class health care facility around the world in order to advance medical care in the UAE.
- **UAE Government Scholarship – Sponsored Oncology Fellowship training at McMaster University**
 Hamilton, Ontario, Canada
 Jul 2010 - Sep 2013
- **UAE Government Scholarship – Sponsored Internal Medicine Residency training at McMaster University**
 Hamilton, Ontario, Canada
 Jul 2007 - Jun 2010

- **UAE Government Scholarship – Sponsored Medical School Education at University College Cork**
Cork, Republic of Ireland
Jul 2007 - Jun 2010

LICENSURE (UAE-CANADA-USA-IRELAND)

- **DUBAI HEALTH AUTHORITY (DHA)**
License number DHA-O-0184997
Consultant Internal Medicine and Medical Oncology – Active
- **DEPARTMENT OF HEALTH ABU DHABI (DOH)**
License # GD11570
Medical Oncology Consultant –Issued 03-Jan-2011; Active
- **MINISTRY OF HEALTH (MOH) – UNITED ARAB EMIRATES**
License # D44393
Medical Oncology Consultant – Active
- **TEXAS MEDICAL BOARD – Texas – USA**
Full License # P7737, Aug 2013 – Expired
- **THE COLLEGE OF PHYSICIANS AND SURGEONS OF ONTARIO – CANADA**
Full License # 86148- Active
- **CERTIFICATE OF REGISTRATION IN THE CANADIAN MEDICAL REGISTER**
Date: 15-Dec-2010
LMCC # 112756
- **EDUCATIONAL COMMISSION FOR FOREIGN MEDICAL GRADUATES (ECFMG) – USA**
Date: 25-Jul-2013
- **THE UNITED STATES MEDICAL LICENSING EXAMINATION**
STEP 1, 2, 3
Completion Date: Aug-2013
- **IRISH MEDICAL COUNCIL**
Fully Registration, 2005 – 2006 – Inactive

UAE NATIONAL LEVEL PROJECTS

- **Dubai Health Authority – Development of Advanced National Oncology Care Standards – 2024**
Contributed to the development and national rollout of advanced regulatory standards for oncology services across Dubai, in collaboration with the Dubai Health Authority (DHA), Prof. Humaid O. Al-Shamsi, and the Emirates Oncology Society, strengthening quality, standardization, and the delivery of cancer care.

<https://www.wam.ae/en/article/b3udh1m-dubai-health-authority-announces-advanced>

- **Ministry of Health and Prevention (MOHAP) – Launch of the UAE’s National Guideline for Lung Cancer Screening and Diagnosis - November 2025**

Played a key role through the Emirates Oncology Society in the development of national guidelines for lung cancer screening and diagnosis, establishing a unified, evidence-based framework for early detection and risk stratification across the UAE.

<https://mohap.gov.ae/en/w/mohap-in-collaboration-with-health-authorities-and-astrazeneca-launches-national-guideline-for-lung-cancer-screening-and-diagnosis>

- **Establishment of the National Multidisciplinary Committee for Cancer Case Assessment – 2025**

Contributed to the establishment of the National Multidisciplinary Committee for Cancer Case Assessment under Ministerial Decree No. (20) of 2025, formalizing multi-disciplinary decision-making and strengthening coordinated cancer care at the national level.

<https://mohap.gov.ae/en/w/ministerial-decree-no.-20-of-the-year-2025-regarding-the-the-criteria-for-establishing-the-national-multidisciplinary-committee-for-cancer-case-assessment-available-in-arabic->

ACHIEVEMENTS AND AWARDS

- **The Dr. Pat Kennedy Award
April 2026**

The inaugural Dr. Pat Kennedy Award was presented in April 2026 in recognition of Prof. Humaid Al-Shamsi’s outstanding contributions to advancing cancer care.

- **Sheikha Fatima bint Mubarak Program for Excellence and Community Intelligence Award (7th Cycle) – Feb 2025**

Category: Honorary Family Category

Awarded by His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, in recognition of outstanding contributions to community leadership and social impact for my role: As President of the Emirates Oncology Society and Executive Director & CEO of Burjeel Cancer Institute.

<https://www.wam.ae/en/article/bieay6y-uae-president-confers-%E2%80%98order-the-mother-the>

- **UAE President receives Professor Humaid Al Shamsi
2025**

<https://www.nmo.gov.ae/en/news/uae-president-receives-professor-humaid-al-shamsi>

- **NAFIS Award – May 2024**

HH Sheikh Mansour bin Zayed Al Nahyan, Vice President of the United Arab Emirates, awarded him the first place in UAE Nafis program for outstanding leadership in private sector across all business and medical disciplines.

<https://gulfnnews.com/business/corporate-news/burjeel-holdings-excels-at-nafis-award-secures-three-first-places-for-emirati-talent-development-1.1715695805906>

- **Feigenbaum Leadership Excellence Awards- Accomplished Leaders – Sheikh Hamdan Bin Mohammed smart University – Mar 2022**
The "Feigenbaum Leadership Excellence Award" is dedicated to honor men and women in the Arab World for their exemplary leadership in driving their organizations to fulfill their role in business and society, for their uncompromising style to instigate a quality approach and culture to work, and for acting as role model to all. The Feigenbaum Leadership Excellence Award is established in honor of Dr. Armand Val Feigenbaum, President and CEO of General Systems Company. Dr. Feigenbaum's considerable experience in the field of leadership and management has led to the design, installation and implementation of proprietary management operating systems to generate greatly improved results in many of the major manufacturing and services companies throughout the world. The Feigenbaum Leadership Excellence Award comprises four leadership categories: Exceptional Leaders. Accomplished Leaders. Women Leaders. Rising Stars.
- **Sharjah award for voluntary work – May 2022**
For Cancer awareness efforts in the UAE and the region
- **UAE Genetic Diseases Association (UAEGDA) distinguished Clinical Award - May 2022**
For his contribution for the advancement of cancer care in the UAE through the establishment of the Bone marrow transplantation unit in the UAE
https://twitter.com/NET_AD/status/1530124525769203712
- **1st Graduate of sheikh Khalifa bin Zayed program for outstanding UAE physicians training program in 2016**
<https://www.albayan.ae/across-the-uae/news-and-reports/2018-02-12-1.3184386>
- **The publication of the year 2020 – Jul 2020**
by the Oncologist Journal "Editor-in-Chief Bruce A. Chabner Massachusetts General Hospital Harvard Medical School Boston, MA" for the publication of "A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group".
<https://theoncologist.onlinelibrary.wiley.com/journal/1549490x/homepage/anniversaryretrospective>
- **The outstanding researcher of the year 2020 by the Emirates Medical Association Sep 2020**
For the publication of over 10 research papers in 2020 mostly in high impact journals.
- **The researcher of the year 2021 by the Emirates Medical Association Sep 2021**
For the publication of over 20 research papers in 2021
<https://eos-uae.com/2nd-eos-annual-conference/>
- **EOS Cancer Awareness Advocate of the Year – 2021**
<https://eos-uae.com/2nd-eos-annual-conference/>
- **Certificate of appreciation from the UAE Embassy in Washington D.C, USA**

For excellence in clinical and research program during the fellowship training at McMaster university 2012

- **MSA (Medical Staff Association) Outstanding Senior Resident of the Year Award McMaster University – Canada 2012**
Nominated by the Medical Oncology department, 3 awards across Hamilton Health Sciences for all postgraduate subspecialties (among a total of 150 trainees).
- **Jeff Ginsberg subspecialty resident Award – McMaster University – Canada 2012**
Nominated by Dr. Som Mukhrjee, Program Director of Medical Oncology training program at McMaster University, 1 award across all Internal Medicine subspecialty.
- **Runner-up, Chief resident of the year - Internal Medicine Training Program 2009-2010**
Nominated for this Award by Hamilton General Hospital's Clinical Teaching Unit (CTU) director for excellent performance in medical education for medical students and junior house staff & administrative performance during the 3 months' chief resident period at the Hamilton General Hospital (Jan 2010 - Mar 2010)
- **Internal Medicine Chief's Cup 2009-2010**
Member of the Hamilton General Hospital Internal Medicine chief's team
- **Certificate of appreciation from the UAE Embassy in London, UK**
For achieving Honors in the Bachelor of Medicine and surgery in 2004 at University College Cork.

RESEARCH AWARDS

- **Stuart Jay Cohen Memorial Award - 1st Place Award**
Student Research Day 2012, Department of Oncology, McMaster University
- **Clinical Research- Poster Presentations**
Venous thromboembolism events in patients with Colorectal Cancer treated with FOLFIRI Plus bevacizumab - JCC Regional cancer center Experience, Supervisor Dr. P. Major.
- **Stuart Jay Cohen Memorial Award – 2nd Place award**
Student Research Day 2012, Department of Oncology, McMaster University
- **Clinical Research – Oral Presentations**
The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer” Supervisor Dr. Alexandra Papaioannou.

PRESENT POSITIONS

- **Member of the Steering committee national cancer control indicators**
Ministry of Health – Dubai – UAE. Jan 2018 – Present
- **Member of the Department of health oncology task force**

Jan 2019 – Present

- **Member of the Editorial Board of the Journal of Global Oncology**
Aug 2017 – Present

REVIEWER

- Cancer Management and Research
- JCO Oncology Practice
- Breast Cancer: Basic and Clinical Research
- International Journal of Clinical Practice
- European Journal of Haematology Editorial Office
- Therapeutic Advances in Medical Oncology

RESEARCH EXPERIENCE

BOOKS:

1. *Al-Shamsi, Humaid O. "Healthcare in the United Arab Emirates"*
<https://link.springer.com/book/10.1007/978-981-96-0523-1>

2. *Al-Shamsi, Humaid O. "Cancer Care in the United Arab Emirates"*
<https://link.springer.com/book/10.1007/978-981-99-6794-0>

3. *Al-Shamsi, Humaid O., Ibrahim H. Abu-Gheida, Faryal Iqbal, and Aydah Al-Awadhi. "Cancer in the Arab World."*

The book has been downloaded more than 500,000 times within the first two years of publication.
<https://link.springer.com/book/10.1007/978-981-16-7945-2>

BOOK CHAPTERS:

1. Al-Shamsi, H.O., and Iqbal, F., 2025. *History of Healthcare in the UAE. In Healthcare in the United Arab Emirates (pp. 1-32). Singapore: Springer Nature Singapore.*
https://link.springer.com/chapter/10.1007/978-981-96-0523-1_1
2. Al-Shamsi, H.O., Al Dhaheri, A., Shersad, F. and Al-Houqani, M., 2025. *National Institute for Health Specialties (NIHS) in the UAE. In Healthcare in the United Arab Emirates (pp. 111-122). Singapore: Springer Nature Singapore.*
https://link.springer.com/chapter/10.1007/978-981-96-0523-1_8
3. Ganesan, S., Al-Shamsi, H.O., Mostafa, M. and Zaher, W.A., 2025. *Research Productivity of Health Sciences Institutions in the UAE: 20-Year-Based Bibliometric Analysis. In Healthcare in the United Arab Emirates (pp. 201-215). Singapore: Springer Nature Singapore.* https://link.springer.com/chapter/10.1007/978-981-96-0523-1_15

4. **Al-Shamsi, H.O.**, Iqbal, F. 2025. *Cancer Care in the UAE*. In: Al-Shamsi, H.O. (eds) *Healthcare in the United Arab Emirates*. Springer, Singapore. https://doi.org/10.1007/978-981-96-0523-1_26
5. Nijhawan, N.A., **Al-Shamsi, H.O.** and Ibrahim, H., 2025. *Palliative and Hospice Medicine in the UAE*. In *Healthcare in the United Arab Emirates* (pp. 413-429). Singapore: Springer Nature Singapore. https://link.springer.com/chapter/10.1007/978-981-96-0523-1_27
6. **Al-Shamsi, H.O.**, Thwaini, A., Iqbal, F., Darwish, O., Rao, A., Janahi, F., Rahman, A.A., Al-Qudah, H. and Al Kasab, T., 2025. *Urology in the UAE*. In *Healthcare in the United Arab Emirates* (pp. 521-543). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-96-0523-1_34
7. Mendonca, V. and **Al-Shamsi, H.O.**, 2025. *The Future of Healthcare in the UAE*. In *Healthcare in the United Arab Emirates* (pp. 841-848). Singapore: Springer Nature Singapore. https://link.springer.com/chapter/10.1007/978-981-96-0523-1_52
8. **Al-Shamsi, H.O.**, 2024. *Introduction*. In: Al-Shamsi, H.O. (eds) *Cancer Care in the United Arab Emirates*. Springer, Singapore. https://doi.org/10.1007/978-981-99-6794-0_1
9. **Al-Shamsi, H.O.** and Abyad, A.M., 2024. *Cancer care in the UAE*. *Cancer Care in the United Arab Emirates*, pp.15-56. https://doi.org/10.1007/978-981-99-6794-0_2
10. Rafii, S. and **Al-Shamsi, H.O.**, 2024. *Cancer prevention, screening, and early detection in the UAE*. In *Cancer care in the united Arab Emirates* (pp. 79-90). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_4
11. **Al-Shamsi, H.O.** and Abyad, A.M., 2024. *A proposal for cancer control plan in the UAE*. In *Cancer care in the United Arab Emirates* (pp. 91-126). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_5
12. **Al-Shamsi, H.O.** and Abyad, A.M., 2024. *Comprehensive Cancer Centers in the UAE*. In *Cancer Care in the United Arab Emirates* (pp. 127-135). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_6
13. **Al-Shamsi, H.O.** and Abyad, A.M., 2024. *Emirates Oncology Society*. In *Cancer Care in the United Arab Emirates* (pp. 137-151). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_7
14. **Al-Shamsi, H.O.**, 2024. *Factors Influencing Seeking Cancer Care Abroad for UAE Citizens*. In *Cancer Care in the United Arab Emirates* (pp. 153-161). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_8
15. Ganesan, S., **Al-Shamsi, H.O.**, Mostafa, M. and Zaher, W.A., 2024. *Clinical cancer research in the UAE*. In *Cancer Care in the United Arab Emirates* (pp. 175-192). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_10

16. **Al-Shamsi, H.O.**, 2024. *Oncology and Hematology Fellowship Training in the UAE. In Cancer Care in the United Arab Emirates* (pp. 209-214). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_12
17. Nijhawan, N.A. and **Al-Shamsi, H.O.**, 2024. *Palliative care in the UAE. In Cancer care in the United Arab Emirates* (pp. 359-376). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_22
18. Al-Awadhi, A., Iqbal, F., Kourie, H.R. and **Al-Shamsi, H.O.**, 2024. *Breast cancer in the UAE. Cancer Care in the United Arab Emirates*, pp.417-434. https://doi.org/10.1007/978-981-99-6794-0_26
19. **Al-Shamsi, H.O.**, Iqbal, F., Kourie, H.R., Zaabi, A.A., Abyad, A.M. and Abdelwahed, N., 2024. *Colorectal cancer in the UAE. In Cancer care in the united arab emirates* (pp. 435-450). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_27
20. Abdelwahed, N., Al Asousi, S., Iqbal, F., Abyad, A.M., Nijhawan, N.A., Kourie, H.R., Abu-Gheida, I.H., Ammori, B. and **Al-Shamsi, H.O.**, 2024. *Gastric cancer in the UAE. In Cancer Care in the United Arab Emirates* (pp. 451-472). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_28
21. **Al-Shamsi, H.O.**, Iqbal, F., Nijhawan, N.A., Kourie, H.R., Abdelwahed, N., Abu-Gheida, I.H. and Ammori, B., 2024. *Pancreatic Cancer in the UAE. In Cancer Care in the United Arab Emirates* (pp. 473-489). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_29
22. Bendardaf, R., Talaat, I.M., Elemam, N.M. and **Al-Shamsi, H.O.**, 2024. *Thyroid Cancer in the UAE. In Cancer Care in the United Arab Emirates* (pp. 545-557). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_32
23. Rafii, S., Aboud, B. and **Al-Shamsi, H.O.**, 2024. *Lung Cancer in the UAE. In Cancer Care in the United Arab Emirates* (pp. 559-568). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_33
24. Sawan, S., Iqbal, F. and **Al-Shamsi, H.O.**, 2024. *Gynecologic Malignancies in the UAE. In Cancer Care in the United Arab Emirates* (pp. 569-580). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_34
25. Shahait, M., Al-Qudah, H., Mula-Hussain, L., Abu-Gheida, I.H., Alkasab, T., Thwaini, A., Madi, R., **Al-Shamsi, H.O.**, Tirmazy, S.H. and Mukherji, D., 2024. *Genitourinary Malignancies in the UAE. In Cancer Care in the United Arab Emirates* (pp. 581-592). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_35
26. Al-Awadhi, A. and **Al-Shamsi, H.O.**, 2024. *Neuroendocrine Tumors (NETs) in the UAE. In Cancer Care in the United Arab Emirates* (pp. 597-601). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_37

27. **Al-Shamsi, H.O.**, Abyad, A.M., Kanakande Kandy, Z.A., George, B., Dar-Yahya, M., Kaloyannidis, P., El-Saddik, A., Rana, S. and Khalil, C., 2024. Hematopoietic Stem Cell Transplantation (HSCT) in the UAE. In *Cancer Care in the United Arab Emirates* (pp. 611-624). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_39
28. **Al-Shamsi, H.O.**, 2024. Suggested Quality Control Measures for Cancer Care in the UAE. In *Cancer Care in the United Arab Emirates* (pp. 629-637). Singapore: Springer Nature Singapore. https://doi.org/10.1007/978-981-99-6794-0_41
29. Abu-Gheida, I.H., Nijhawan, N., Al-Awadhi, A. and **Al-Shamsi, H.O.**, 2022. General oncology care in the UAE. In *Cancer in the Arab world* (pp. 301-319). Singapore: Springer Singapore. https://doi.org/10.1007/978-981-16-7945-2_19
30. **Al-Shamsi, H.O.** and Iqbal, F., 2022. General Oncology Care in Qatar, Comoros, and Djibouti. In *Cancer in the Arab World* (pp. 339-352). Singapore: Springer Singapore. https://doi.org/10.1007/978-981-16-7945-2_21
31. **Al-Shamsi, H.O.**, Iqbal, F., Abu-Gheida, I.H. 2022. Introduction. In: *Al-Shamsi, H.O., Abu-Gheida, I.H., Iqbal, F., Al-Awadhi, A. (eds) Cancer in the Arab World*. Springer, Singapore. https://doi.org/10.1007/978-981-16-7945-2_1
32. Nijhawan, N.A. and **Al-Shamsi, H.O.**, 2021. Palliative care in the united Arab Emirates (UAE). In *Handbook of healthcare in the Arab world* (pp. 2315-2332). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-319-74365-3_102-1
33. Abu-Gheida, I., Nijhawan, N.A. and **Al-Shamsi, H.O.**, 2021. Oncology care in the UAE. In *Handbook of healthcare in the Arab world* (pp. 521-538). Cham: Springer International Publishing. https://doi.org/10.1007/978-3-319-74365-3_183-1
34. **Al-Shamsi, H.**, Hansel, D.E., Bellmunt, J. and Siefker-Radtke, A.O. (2017). Uncommon Cancers of the Bladder. In *Textbook of Uncommon Cancer* (eds D. Raghavan, M.S. Ahluwalia, C.D. Blanke, J. Brown, E.S. Kim, G.H. Reaman and M.A. Sekeres). <https://doi.org/10.1002/9781119196235.ch5>
35. **Humaid Al-Shamsi**, Siefker-Radtke A, Czerniak B, Dinney C, Millikan RE. *Uncommon Cancers of the Bladder*. In: *Textbook of Uncommon Cancer, 5th ed.* Ed(s) Raghavan D, Brecher ML, Johnson DH, Meropol NJ, Moots PL, Rose PG, Mayer IA. John Wiley and Son, 2016.

PEER REVIEWED PUBLICATIONS:

For the UpToDate list, please visit:

https://scholar.google.com/citations?hl=en&user=1zpLCSIAAAAJ&view_op=list_works&sortby=pubdate

1. Jarrah, M.M., **Al-Shamsi, H.O.**, Abuhelwa, Z., Bustanji, Y., Semreen, M.H., McKinnon, R.A., Sorich, M.J., Hopkins, A.M. and Abuhelwa, A.Y., 2026. Treatment-Specific Prediction Models in Multiple Myeloma: A Critical Review of Current Evidence and Future Directions.

European Journal of Haematology.
<https://onlinelibrary.wiley.com/doi/full/10.1111/ejh.70177>

2. Abuhelwa, A.Y., Almansour, S.A., **Al-Shamsi, H.O.**, Abuhelwa, Z., Alqudah, M.A., Bustanji, Y., Semreen, M.H., Alzoubi, K.H., Modi, N.D., McKinnon, R.A. and Sorich, M.J., 2026. Cardiovascular medications and treatment outcomes in multiple myeloma: insights from phase III clinical trials. *Scientific Reports*. <https://doi.org/10.1038/s41598-026-37464-4>
3. Moshi, J.M., Abdelwahab, S.I., Taha, M.M.E., Alamer, D.A., Maashi, H.M., Badri, R.M., Jeraiby, M., Maashi, S.M., Majrashi, E.J.M., Bajawi, Y.A. and **Al-Shamsi, H.O.**, 2026. Breast Cancer Awareness and Screening Predictors in Young Saudi Women: Findings From a Cross-Sectional Study. *Health Science Reports*, 9(3), p.e71831. <https://doi.org/10.1002/hsr2.71831>
4. Abuhelwa, A.Y., Almansour, S.A., **Al-Shamsi, H.O.**, Abuhelwa, Z., Ziade, M.A., McKinnon, R.A., Sorich, M.J. and Hopkins, A.M., 2026. HSR26-204: Baseline EORTC QLQ-C30 “Clinically Important” Symptom Burden Predicts Survival and Toxicity in CLL/SLL Across Randomized Ibrutinib Trials. *Journal of the National Comprehensive Cancer Network*, 24(3.5). <https://doi.org/10.6004/jnccn.2025.7459>
5. Abdelwahab, S.I., Taha, M.M.E., Farasani, A., Abdullah, S.M., Alshahrani, S., Assiri, A., Moshi, J.M., Khamjan, N.A., **Al-Shamsi, H.**, Alshahrani, A.F. and Mohan, S., 2026. Emerging Trends and Conceptual Mapping in Network Pharmacology Research: A Bibliometric Analysis (2008-2023) Using VOSviewer. *Ind. J. Pharm. Edu. Res*, 60(2s), pp.s651-s662. DOI: 10.5530/ijper.20262593. <https://nchr.elsevierpure.com/en/publications/emerging-trends-and-conceptual-mapping-in-network-pharmacology-re/>
6. **Al-Shamsi, H.O.**, Rasul Snr, K., Shablak, A., ALnajjar, A., Shabaan, A.M.A., Al Sindi, M., Nasr, M., AlJabban, A. and Rafii, S., 2025. Diagnosis and Management of Colorectal Cancer in the Gulf Area: Current Practice and Future Suggestions from Expert Opinions. *OncoTargets and Therapy*, pp.1265-1279. <https://doi.org/10.2147/ott.s535858>
7. Latif, M.F., Tirmazy, S.H., Hamza, D.M., Das, K., Omara, M., Basit, A., Saber, N. and **Al-Shamsi, H.O.**, 2025. 59eP Correlation between Oncotype Dx recurrence score and clinicopathological factors in early breast cancer: A retrospective single institution study, Dubai Hospital, Dubai, UAE. *Annals of Oncology*, 36, p.S1784. <https://doi.org/10.1016/j.annonc.2025.10.893>
8. Rafii, S., Mukherji, D., Komaranchath, A.S., Khalil, C., Iqbal, F., Abdelwahab, S.I., Abyad, A., Abuhelwa, A.Y., Gandikota, L. and **Al-Shamsi, H.O.**, 2025. Advancing CAR T-cell therapy in solid tumors: current landscape and future directions. *Cancers*, 17(17), p.2898. <https://doi.org/10.3390/cancers17172898>
9. Syrigos, K.N., Bussell, M.E., **Al-Shamsi, H.O.**, Khorshid, O., Herbst, R.S., Agelaki, S., Leighl, N., Hirsch, F. and Wakelee, H., 2025. Bridging the gap in lung cancer: A comprehensive global strategy for change. *European Journal of Cancer*, p.116069. <https://doi.org/10.1016/j.ejca.2025.116069>

10. Moshi, J.M., Abdelwahab, S.I., Taha, M.M.E., Albasheer, O., Abdullah, S.M., Farasani, A., Jeraiby, M.A., **Al-Shamsi, H.O.**, Hakami, A.M.S., Khamjan, N.A. and Alshahrani, S., 2025. Cancer research in Saudi Arabia: A cross-sectional mapping study of historical growth, thematic analysis, collaboration patterns, and future directions. *Medicine*, 104(39), p.e44757. DOI: 10.1097/MD.00000000000044757. https://journals.lww.com/md-journal/fulltext/2025/09260/cancer_research_in_saudi_arabia_a_cross_sectional.36.aspx
11. Mukherji, D., Agarwal, M., **Al-Shamsi, H.O.**, Angel, M., Da Rosa, D.A.R., Limaye, S., Talreja, V., El Morsi, W., Ürün, Y. and Grande, E., 2026. Social media for healthcare professionals in oncology: results from a cross-sectional survey conducted across eight countries in Asia, Latin America, and the Middle East. *Future Oncology*, 22(2), pp.203-216. <https://doi.org/10.1080/14796694.2025.2548192>
12. Kandy, Z.A.K., Nivargi, S., Chaudhary, B., Ramzan, M., Abdullah, F., Aboobacker, F., Khalil, C., Porta, F., Faulkner, L. and **Alshamsi, H.**, 2025. Outcomes of hematopoietic stem cell transplantation (HSCT) from matched related donors in pediatric patients: insights from a single center in the United Arab Emirates. *Cureus*, 17(8). DOI: 10.7759/cureus.89239. <https://www.cureus.com/articles/372874#!/>
13. Jagadeesan, S., Kalyanasundaram, K., Alghamdi, M., Mohammed, M., Sweidan, R., Abdalqader, A., Sonawane, Y., **Al-Shamsi, H.** and Abu-Gheida, I., 2025. Feasibility of a robust and homogeneous volumetric modulated arc therapy based total body irradiation technique and analysis of dose rate using Elekta solutions. *Medical Dosimetry*. <https://doi.org/10.1016/j.meddos.2025.06.003>
14. Shehab, A., Al Dhanhani, H., Alhammadi, O., Hassan, M.B., Farghaly, M., Hassoun, A., Mahboub, B., Tahlak, M., Abutayeh, R.F., Haridy, H., Hassanien, A., Joury J., **Al-Shamsi, H. O.** 2025. Strategies for the Prevention and Management of Respiratory Infections in Patients at High Risk in the UAE: A Cross-Disciplinary Position Paper. *Pulmonary Therapy*, 11(3), pp.405-421. <https://doi.org/10.1007/s41030-025-00304-3>
15. Abdelwahab, S.I., Moni, S.S., Taha, M.M.E., Sahli, K.A., Alqhtani, H.A.S., Farasani, M.M., Qadri, M., Alarif, A., Khardali, A., Alsaadi, K.H., Farasani, A., Khamjan A. Nizar., **Al-Shamsi, H. O.** et al. 2025. Mapping breast cancer research on monoclonal antibodies: a data-driven approach using VOSviewer, Bibliometrix, and CiteSpace. *Naunyn-Schmiedeberg's Archives of Pharmacology*, pp.1-21. <https://doi.org/10.1007/s00210-025-04401-7>
16. Mukherji, D., Fadhil, I., Faraj, W., Rafii, S. and **Al-Shamsi, H.O.**, 2025. Cancer control in the United Arab Emirates. *The Lancet Oncology*. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(25\)00077-4/abstract](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00077-4/abstract)
17. Shreenivas AV, Cristofanilli M, Limaye SA, Gaya AM, Crook T, Ajami R, Mokbel K, Schaffrin-Nabe D, **Al-Shamsi H.O.**, Mandal TK, Shingla S. Molecular profiling of body fluid cfDNA: Advancing diagnostics and therapeutic decisions. https://doi.org/10.1200/JCO.2025.43.16_suppl.3054
18. Patil, D., Grewal, U.S., Vaid, A.K., Advani, S.H., Shingla, S., Varshney, A.N., Gaya, A.M., **Al-Shamsi, H.O.**, Wilson, J., Mandal, T.K. and Crook, T., 2025. Molecular diversity in

neuroendocrine tumors: A house divided.
https://ascopubs.org/doi/pdf/10.1200/JCO.2025.43.16_suppl.e15170

19. Abuhelwa, A.Y., Almansour, S.A., Basch, E., **Al-Shamsi, H.O.**, Abuhelwa, Z., Bustanji, Y., Semreen, M.H., Kharaba, Z., Ali, S.M., Mohamed, R. and Kichenadasse, G., 2025. Predictive and Prognostic Significance of Patient-Reported Outcomes for Survival and Adverse Events in Daratumumab-Treated Multiple Myeloma. *European Journal of Haematology*, 114(6), pp.1020-1031. <https://doi.org/10.1111/ejh.14410>
20. Abdelwahab, S.I., Taha, M.M.E., Sahli, K.A., Alqhtani, H.A.S., Farasani, A., Khamjan, N.A., **Al-Shamsi, H.**, Moshi, J.M., Alshahrani, S., Assiri, A. and Qadri, M., 2025. Graphene-based biosensors for PSA. *Clinica Chimica Acta*, 576, p.120406. <https://doi.org/10.1016/j.cca.2025.120406>
21. Abuhelwa, A.Y., Almansour, S.A., Brown, J.R., **Al-Shamsi, H.O.**, Abuhelwa, Z., Kharaba, Z., Bustanji, Y., Semreen, M.H., Ali, S., Alhurairi, A. and McKinnon, R.A., 2025. Statin use and survival in CLL/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials. *Blood advances*, 9(14), pp.3566-3575. <https://doi.org/10.1182/bloodadvances.2024015287>
22. El-Deiry W.S., Bresson C., Wunder F., Carneiro B.A., Dizon D.S., Warner J.L., Graff S.L., Azzoli C.G., Wong E.T., Cheng L., Mani S.A., Safran H.P., Williams C., Meissner T., Solomon B., Rubin E., Porgador A., Berchem G., Saintigny P., Onn A., Bar J., Berger R., Gantenbein M., Chen Z., Souza C.P., Reis R.M.V., Sekacheva M., Cervantes A., Dahut W.L., Annunziata C.M., Gober K., Musallam KM., **Al-Shamsi H.O.**, Abu-Gheida I., Salazar R., et. Al. 2025. Worldwide innovative network (WIN) consortium in personalized cancer medicine: bringing next-generation precision oncology to patients. *Oncotarget*, 16, p.140. <https://doi.org/10.18632/oncotarget.28703>
23. **Al-Shamsi, H.O.**, Abdelwahed, N. and Mokbel, K., 2025. Surveillance Systemic Imaging After Curative Intent for Breast Cancer: A Double Standard?. *Journal of Clinical Oncology*, 43(1), pp.109-111. <https://doi.org/10.1200/JCO.24.01186>
24. Nijhawan, N.A., **Al-Shamsi, H.**, Sweeting, K., Mustafa, R., Sheikh, A., Khan, J.K., Tareen, M., Safi, A.M. and Hami, F., 2025. Palliative care in United Arab Emirates: Response to The Lancet Commission on the value of death. *Eastern Mediterranean Health Journal*, 31(12), pp.666-668. <https://doi.org/10.26719/2025.31.12.666>
25. **Al-Shamsi, H.O.**, Oner, M. and Mokbel, K., 2025. Balancing evidence and individualization in adjuvant CDK4/6 therapy. *Translational Cancer Research*, 14(8), pp.4479-4481. <https://doi.org/10.21037/tcr-2025-879>
26. **Al-Shamsi, H.O.**, Patil, D.S., Limaye, S., Vaid, A.K., Datar, R., Fuller-Shavel, N., Lechner, M., Krupashankar, S., Shah, D.K., Shingla, S. and Datta, A., 2025. 151P Exosomal miRNA-based classification of breast cancer subtypes in patients unsuitable for tissue biopsy. *Annals of Oncology*, 36, p.S266. <https://doi.org/10.1016/j.annonc.2025.08.585>
27. Limaye, S., Datar, R., Syed, N., Ghaisas, A., Akolkar, D., Chougule, R., ... & **Al-Shamsi, H. O.** 2025. 1747P Real-world performance of an AI-driven U-Net-Based pipeline for

automated detection of circulating tumor cells (CTCs) in a screening population. *Annals of Oncology*, 36, p.S1025. <https://doi.org/10.1016/j.annonc.2025.08.2376>

28. Kaloyannidis, P., George, B., Alrustamani, A., Khalil, C., Al-Charfli, B., Al-Moghrabi, N., ... & **Al-Shamsi, H.O.** 2024. Paving the Road for Haematopoietic Stem Cell Transplantation in the United Arab Emirates: A Single Centre's Experience. *Journal of Blood Medicine*, pp.471-475. <https://doi.org/10.2147/jbm.s468665>
29. Albaldawy, M.J., Ebaied, T., **Al Shamsi, H.O.**, Nadaf, A., Abbu, R.U.F. and Al Shamsi, H.O., 2024. Adult-Onset Pediatric-Type Follicular Lymphoma of the Parotid Gland. *Cureus*, 16(12). <https://doi.org/10.7759/cureus.76161>
30. Abusanad, A., Alawadi, A., Mukharji, D., Abualkair, O., Almansoori, N., Alsindi, M. and **Al-Shamsi, H.O.**, 2024. Insights and solutions for advancing and empowering women in oncology from the Gulf Cooperation Council Countries. *ESMO open*, 9(10), p.103723. <https://doi.org/10.1016/j.esmoop.2024.103723>
31. Almansour, S.A., Alqudah, M.A., Abuhelwa, Z., **Al-Shamsi, H.O.**, Alhuraiji, A., Semreen, M.H., Bustanji, Y., Alzoubi, K.H., Modi, N.D., Mckinnon, R.A. and Sorich, M.J., 2024. Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials. *Therapeutic Advances in Medical Oncology*, 16, p.17588359241275387. <https://doi.org/10.1177/17588359241275387>
32. **Al-Shamsi, H.O.** and Musallam, K.M., 2024. Not only a Western world issue: Cancer incidence in younger individuals in the United Arab Emirates. *CA: A Cancer Journal for Clinicians*, 74(3). <https://doi.org/10.3322/caac.21839>
33. **Al-Shamsi, H.O.**, Abdelwahab, S.I., Albasheer, O., Taha, M.M.E., Alqassim, A.Y., Alharbi, A., Farasani, A., Altraifi, A.A.A., Medani, I.E., Hakami, N. and Abdelmola, A.O., 2024. Cancer research in the United Arab Emirates from birth to present: A bibliometric analysis. *Heliyon*, 10(6). <https://doi.org/10.1016/j.heliyon.2024.e27201>
34. Allehebi, A., Al-Omair, A., Mahboub, B., Koegelenberg, C.F., Mokhtar, M., Madkour, A.M., Al-Asad, K., Selek, U. and **Al-Shamsi, H.O.**, 2024. Recommended approaches for screening and early detection of lung cancer in the Middle East and Africa (MEA) region: a consensus statement. *Journal of Thoracic Disease*, 16(3), pp.2142-2158. <https://pmc.ncbi.nlm.nih.gov/articles/PMC11009596/>
35. Laguna, J.C., Garcia-Pardo, M., Alessi, J., Barrios, C., Singh, N., **Al-Shamsi, H.O.**, Loong, H., Ferriol, M., Recondo, G. and Mezquita, L., 2024. Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. *Therapeutic advances in medical oncology*, 16, p.17588359241231260. <https://doi.org/10.1177/17588359241231260>
36. Almansour, S.A., Alqudah, M.A., Abuhelwa, Z., **Al-Shamsi, H.O.**, Semreen, M.H., Bustanji, Y., Soare, N.C., McKinnon, R.A., Sorich, M.J., Hopkins, A.M. and Abuhelwa, A.Y., 2024. Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: pooled analysis of three clinical trials. *Scientific Reports*, 14(1), p.591. <https://doi.org/10.1038/s41598-023-48640-1>

37. **Al-Shamsi, H.O.**, Abdelwahed, N., Abyad, A., Abu-Gheida, I., Afrit, M., Abu ElFuol, T., Alasas, R., Lababidi, B., Dash, P., Ahmad, M., Dreier, N.W., et al. 2023. Breast cancer in the Arabian Gulf countries. *Cancers*, 15(22), p.5398. <https://doi.org/10.3390/cancers15225398>
38. Abbas, N.F., Aoude, M.R., Kourie, H.R. and **Al-Shamsi, H.O.**, 2024. Uncovering the epidemiology of bladder cancer in the Arab world: A review of risk factors, molecular mechanisms, and clinical features. *Asian Journal of Urology*, 11(3), pp.406-422. <https://doi.org/10.1016/j.ajur.2023.10.001>
39. **Al-Shamsi, H.O.**, Abdelwahed, N., Singh, M., Abyad, A.M., Elsabae, S., Abdelgawad, T., Iqbal, F., Ibrahim, N. 2023. First reported case of successful conception and delivery during stage IV breast cancer treatment: A case report and literature review. *Cureus*, 15(10). <https://doi.org/10.7759/cureus.47201>
40. **Al-Shamsi, H.O.**, Abu-Gheida, I., Sameh, K., Tahoun, N.E. and Musallam, K.M., 2023. Arab countries and oncology clinical trials: A bibliometric analysis. *Cancers*, 15(18), p.4428. <https://doi.org/10.3390/cancers15184428>
41. Elkaddoum, R., Zakhour, J., Hajal, M., Aoun, M., Njeim, M., Mahrous, M., **Al-Shamsi, H.O.**, Brahim, Z.B., Khatib, S.A. and Kourie, H.R., 2023. Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey. *Pharmacogenomics*, 24(13), pp.725-730. <https://pubmed.ncbi.nlm.nih.gov/37706248/>
42. Kourie, H.R., Mahrous, M., Naim, N., Zouein, J., Benbrahim, Z., Rasul, K., Mokhtar, M., Shehri, A.A., Shakeeb, M., Khatib, S. and **Al-Shamsi, H.**, 2023. The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer. <https://pubmed.ncbi.nlm.nih.gov/37526151/>
43. Humaid Al-Shamsi, S., Humaid Al-Shamsi, A., Humaid Al-Shamsi, M., Sajwani, A., Alzaabi, M.S., Al Hammadi, O., Iqbal, F. and **Al-Shamsi, H.O.**, 2023. The perception and awareness of the public about cancer and cancer screening in the United Arab Emirates, a population-based survey. *Clinics and Practice*, 13(3), pp.701-714. <https://doi.org/10.3390/clinpract13030064>
44. Bernstein, E., Lev-Ari, S., Shapira, S., Leshno, A., Sommer, U., **Al-Shamsi, H.**, Shaked, M., Segal, O., Galazan, L., Hay-Levy, M., Srer, M., et al. 2023. Data from a one-stop-shop comprehensive cancer screening center. *Journal of Clinical Oncology*, 41(14), pp.2503-2510. <https://doi.org/10.1200/JCO.22.00938>
45. Albarrak, J. and **Al-Shamsi, H.**, 2023. Current status of management of hepatocellular carcinoma in the Gulf region: challenges and recommendations. *Cancers*, 15(7), p.2001. <https://doi.org/10.3390/cancers15072001>
46. Abboud, K., Umoru, G., Esmail, A., Abudayyeh, A., Murakami, N., **Al-Shamsi, H.O.**, Javle, M., Saharia, A., Connor, A.A., Kodali, S., Ghobrial, R.M., and Abdelrahim M. 2023. Immune checkpoint inhibitors for solid tumors in the adjuvant setting: current progress, future

- directions, and role in transplant oncology. *Cancers*, 15(5), p.1433. <https://doi.org/10.3390/cancers15051433>
47. Park, S.H., Hong, S.H., Kim, K., Lee, S.W., Yon, D.K., Jung, S.J., Abdeen, Z., Ghayda, R.A., Ahmed, M.L.C.B., Serouri, A.A., Al-Herz, W., **Al-Shamsi, H.O.**, Ali, S., et al. 2023. Nonpharmaceutical interventions reduce the incidence and mortality of COVID-19: A study based on the survey from the International COVID-19 Research Network (ICRN). *Journal of Medical Virology*, 95(2), p.e28354. <https://doi.org/10.1002/jmv.28354>
48. Halaseh, S.A., Al-Karadsheh, A., Mukherji, D., Alhjahaja, A., Farkouh, A.A., Al-Ibraheem, A., Gheida, I.A., Al-Khateeb, S., **Al-Shamsi, H.** and Shahait, M., 2023. Prostate cancer clinical trials in low-and middle-income countries. *ecancermedicalsecience*, 17, p.1629. <https://doi.org/10.3332/ecancer.2023.1629>
49. Baqain, L., Mukherji, D., **Al-Shamsi, H.O.**, Abu-Gheida, I., Al Ibraheem, A., Al Rabii, K., Farkouh, A.A. and Shahait, M., 2023. Quality and reliability of YouTube videos in Arabic as a source of patient information on prostate cancer. *ecancermedicalsecience*, 17, p.1573. <https://pmc.ncbi.nlm.nih.gov/articles/PMC10393303/>
50. **Al-Shamsi, H.O.**, Abdelwahed, N., Al-Awadhi, A., Albashir, M., Abyad, A.M., Rafii, S., Afrit, M., Al Lababidi, B., Abu-Gheida, I., Sonawane, Y.P., Nijhawan, N.A., et al. 2023. Breast cancer in the United Arab Emirates. *JCO Global Oncology*, 9, p.e2200247. <https://doi.org/10.1200/GO.22.00247>
51. Nijhawan, N.A. and **Al-Shamsi, H.O.**, 2022. Experiences and challenges of a new palliative care service in the United Arab Emirates. *Palliative Medicine and Hospice Care—Open Journal*, 8(2), pp.30-34. <http://dx.doi.org/10.17140/PMHCOJ-8-150>
52. **Al-Shamsi, H.O.**, 2022. The state of cancer care in the United Arab Emirates in 2022. *Clinics and practice*, 12(6), pp.955-985. <https://doi.org/10.3390/clinpract12060101>
53. **Al-Shamsi, H.O.**, 2022. Barriers and facilitators to conducting oncology clinical trials in the UAE. *Clinics and Practice*, 12(6), pp.885-896. <https://doi.org/10.3390/clinpract12060093>
54. AlZaabi, A., AlHarrasi, A., AlMusalami, A., AlMahyijari, N., Al Hinai, K., ALAdawi, H. and **Al-Shamsi, H.O.**, 2022. Early onset colorectal cancer: challenges across the cancer care continuum. *Annals of Medicine and Surgery*, 82. <https://pubmed.ncbi.nlm.nih.gov/36268309/>
55. Ennab, F., Tsagkaris, C., Babar, M.S., Tazyeen, S., Kokash, D., Nawaz, F.A. and **Al-Shamsi, H.O.**, 2022. A potential rise of breast cancer risk in the UAE post-COVID-19 lockdown: A call for action. *Annals of Medicine and Surgery*, 79, p.103976. <https://doi.org/10.1016/j.amsu.2022.103976>
56. Aoude, M., Mousallem, M., Abdo, M., Youssef, B., Kourie, H.R. and **Al-Shamsi, H.O.**, 2022. Gastric cancer in the Arab World: a systematic review. *Eastern Mediterranean Health Journal*, 28(7), pp.521-531. <https://iris.who.int/handle/10665/361808>

57. Abou Ghayda, R., Lee, K.H., Han, Y.J., Ryu, S., Hong, S.H., Yoon, S., Jeong, G.H., Yang, J.W., Lee, H.J., Lee, J., Lee, J.Y., Effenberger, M., Eisenhut, M., Kronbichler, A., Solmi, M., Li, H., Jacob, L., Koyanagi, A., Radua, J., Park, M.B., Aghayeva, S., Ahmed, MLCB., Al Serouri, A., **Al-Shamsi H.O.**, Amir-Behghadami, M., et al. 2022. The global case fatality rate of coronavirus disease 2019 by continents and national income: A meta-analysis. *Journal of medical virology*, 94(6), pp.2402-2413. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9015248/>
58. Al Ashour, B.H., Azam, F., Ibnshamsah, F., Alrowais, F., Al-Garni, A., Al-Shamsi, H.O., Bukhari, N., Ibnshamsa, F., Algarni, A.A. and **Al-shamsi, H.**, 2022. Metastatic type II papillary renal cell carcinoma with recurrent complete responses to sunitinib: a case report with a literature review. *Cureus*, 14(5). <https://pmc.ncbi.nlm.nih.gov/articles/PMC9246320/>
59. Mula-Hussain, L., Mahdi, H., Ramzi, Z.S., Tolba, M., Zaghoul, M.S., Benbrahim, Z., Abusanad, A., **Al-Shamsi, H.**, Bounedjar, A. and Jazieh, A.R., 2022. Cancer burden among Arab world males in 2020: The need for a better approach to improve outcome. *JCO Global Oncology*, 8, p.e2100407. <https://doi.org/10.1200/GO.21.00407>
60. Allehebi, A., Al Kattan, K., Al Rujuib, M., Al Dayel, F., Black, E., Mahrous, M., AlNassar, M., Al Hussaini, H., Al Twaigi, A., Abdelhafeiz, N., Al Omair, A., Shehri, SA., **Al-Shamsi, H.O.**, Jazieh, A.R. 2022. Management of early-stage resected non-small cell lung cancer: Consensus statement of the lung cancer consortium. *Cancer Treatment and Research Communications*, 31, p.100538. <https://doi.org/10.1016/j.ctarc.2022.100538>
61. **Al-Shamsi, H.O.**, Abyad, A.M. and Rafii, S., 2022. A proposal for a National Cancer Control Plan for the UAE: 2022–2026. *Clinics and Practice*, 12(1), pp.118-132. <https://doi.org/10.3390/clinpract12010016>
62. Rafii, S., Tashkandi, E., Bukhari, N. and **Al-Shamsi, H.O.**, 2022. Current status of CRISPR/Cas9 application in clinical cancer research: opportunities and challenges. *Cancers*, 14(4), p.947. <https://doi.org/10.3390/cancers14040947>
63. **Al-Shamsi, H.O.**, Abyad, A., Kaloyannidis, P., El-Saddik, A., Alrustamani, A., Abu Gheida, I., Ziade, A., Dreier, N.W., Ul-Haq, U., Joshua, T.L.A., El Kinge, A.R., et al. 2022. Establishment of the first comprehensive adult and pediatric hematopoietic stem cell transplant unit in the United Arab Emirates: rising to the challenge. *Clinics and Practice*, 12(1), pp.84-90. <https://doi.org/10.3390/clinpract12010010>
64. Ramia, P., Bodgi, L., Mahmoud, D., Mohammad, M.A., Youssef, B., Kopek, N., **Al-Shamsi, H.**, Dagher, M. and Abu-Gheida, I., 2022. Radiation-induced fibrosis in patients with head and neck cancer: a review of pathogenesis and clinical outcomes. *Clinical Medicine Insights: Oncology*, 16, p.11795549211036898. <https://doi.org/10.1177/11795549211036898>
65. Elsamany, S., Elbaiomy, M., Zeeneldin, A., Tashkandi, E., Hassanin, F., Abdelhafeez, N., **Al-Shamsi, H.**, Bukhari, N. and Elemam, O., 2021. Suggested modifications to the management of patients with breast cancer during the COVID-19 pandemic: web-based survey study. *JMIR cancer*, 7(4), p.e27073. <https://doi.org/10.2196/27073>

66. Hodroj, M.H., El Hasbani, G., **Al-Shamsi, H.O.**, Samaha, H., Musallam, K.M. and Taher, A.T., 2022. Clinical burden of hemophilia in older adults: Beyond bleeding risk. *Blood Reviews*, 53, p.100912. <https://doi.org/10.1016/j.blre.2021.100912>
67. **Al-Shamsi, H.O.**, Jaffar, H., Mahboub, B., Khan, F., Albastaki, U., Hammad, S. and Zaabi, A.A., 2021. Early diagnosis of lung cancer in the United Arab Emirates: challenges and strategic recommendations. *Clinics and Practice*, 11(3), pp.671-678. <https://doi.org/10.3390/clinpract11030082>
68. **Al-Shamsi, H.O.**, Abu-Gheida, I., Abdulsamad, A.S., AlAwadhi, A., Alrawi, S., Musallam, K.M., Arun, B. and Ibrahim, N.K., 2021. Molecular spectra and frequency patterns of somatic mutations in Arab women with breast cancer. *The oncologist*, 26(11), pp.e2086-e2089. <https://doi.org/10.1002/onco.13916>
69. **Al-Shamsi, H.O.**, Eric, A. 2021. Successful Vaccination of Patients with History of Severe Anaphylactic Reaction with Pfizer-Biotech COVID-19 Vaccine. *Journal of Oncology Research Review & Reports*. SRC/JONRR-125. occur up to, 20. https://www.researchgate.net/publication/364024481_Successful_Vaccination_of_Patients_with_History_of_Severe_Anaphylactic_Reaction_with_Pfizer-Biotech_COVID-19_Vaccine
70. **Al-Shamsi, H. O.**, Alzaabi, A. A., Afrit, M., Abu-Gheida, I., & Musallam, K. M. (2021). Clinicopathological features of gastric cancer in a cohort of Gulf Council countries' patients: a cross-sectional study of 96 cases. *Journal of Oncology Research Review Reports*. SRC/JONRR-133, 3. https://www.researchgate.net/publication/351980181_Clinicopathological_Features_of_Gastric_Cancer_in_a_Cohort_of_Gulf_Council_Countries'_Patients_A_Cross-Sectional_Study_of_96_Cases
71. **Al-Shamsi, H.**, Azribi, F., Abu-Gheida, I., Jaafar, H. and Razek, A.A., 2021. The Emirates Oncology Task Force Clinical Practice Guideline on Screening for SARS-CoV-2 in Asymptomatic Adult Cancer Patients Prior to Anti-Cancer Therapy. *Journal of Oncology Research Review & Reports*. SRC/JONRR-137, 3.
72. **Al-Shamsi, H.O.**, Iqbal, F., Al Saad, M.S., Dhemre, P.A., Hachem, F.G., et al. 2021. The burden of gynecologic cancers in the UAE. *Journal of Oncology Research Reviews & Reports*. SRC/JONRR-147. DOI: doi. org/10.47363/JONRR/2021 (2), 143, pp.2-6. <https://cancercarespecialtiesmena.com/wp-content/uploads/2023/02/the-burden-of-gynecologic-cancers-in-the-uae.pdf>
73. Bukhari, N., Alshangiti, A., Tashkandi, E., Algarni, M., **Al-Shamsi, H.O.** and Al-Khallaf, H., 2021. Fluoropyrimidine-induced severe toxicities associated with rare DPYD polymorphisms: case series from Saudi Arabia and a review of the literature. *Clinics and Practice*, 11(3), pp.467-471. <https://doi.org/10.3390/clinpract11030062>
74. Azhar, M., Aziz, F., Almuhairi, S., Alfelasi, M., Elhouni, A., Syed, R., **Al-Shamsi, H.O.** and Aldahmani, K.M., 2021. Decline in radioiodine use but not total thyroidectomy in thyroid cancer patients treated in the United Arab Emirates-A retrospective study. *Annals of Medicine and Surgery*, 64, p.102203. <https://doi.org/10.1016/j.amsu.2021.102203>

75. **Al-Shamsi, H.O.**, Coomes Eric A. 2021. Higher and Increasing Incidence of Cancer between the Age of 20-49 Years in the UAE Population; A focus Analysis of the UAE National Cancer Registry Data 2015-2017. *Journal of Oncology Research Review & Reports. SRC/JONRR-127*, 3.
76. **Al-Shamsi, H.O.**, Sadir Alrawi S., Abdulsamad Ahmed S., Ibrahim, N.k. 2021. A Strong Beliefs and Soft Evidence Underlying Mammography Surveillance Recommendations in Breast Cancer Survivors: A Study in Reflexive Science and Decision-Making. *Journal of Oncology Research Review & Reports. SRC/JONRR-131*, 3.
77. Bernstein, E., Shapira, S., Lev-Ari, S., Leshno, A., Sommer, U.A., Galazan, L., **Al-Shamsi, H.O.**, Wolf, I., Shaked, M., Hay Levy, M., Srer, M., et al. 2021. One-stop-shop for cancer screening: A model for the future. DOI: 10.1200/JCO.2021.39.15_suppl.10554. <https://www.asco.org/abstracts-presentations/196770>
78. Latif, M.F., Azam, F., Tirmazy, S.H., Bashir, S., Ibnshamsah, F., Al Selwi, W.M., Bukhari, N., Alwbari, A., Alshangiti, A., Gabsi, A. and **Al-Shamsi, H.O.**, 2021. Impact of COVID 19 pandemic on psychological wellbeing of oncology clinicians in MENA (Middle East and North Africa) region. https://doi.org/10.1200/JCO.2021.39.15_suppl.e24105
79. **Al-Shamsi, H.**, Darr, H., Abu-Gheida, I., Ansari, J., McManus, M.C., Jaafar, H., Tirmazy, S.H., Elkhoury, M., Azribi, F., Jelovac, D., Doufan, T.A., et al. 2020. The State of Cancer Care in the United Arab Emirates in 2020: Challenges and Recommendations, A report by the United Arab Emirates Oncology Task Force. *The Gulf journal of oncology*, 1(32), pp.71-87. <https://pubmed.ncbi.nlm.nih.gov/32342923/>
80. **Al-Shamsi, H.O.**, Coomes, E.A. and Alrawi, S., 2020. Screening for COVID-19 in asymptomatic patients with cancer in a hospital in the United Arab Emirates. *JAMA oncology*, 6(10), pp.1627-1628. <https://jamanetwork.com/journals/jamaoncology/fullarticle/2766703>
81. **Al-Shamsi, H.O.**, Coomes, E.A., Aldhaheeri, K. and Alrawi, S., 2021. Serial screening for COVID-19 in asymptomatic patients receiving anticancer therapy in the United Arab Emirates. *JAMA oncology*, 7(1), pp.129-131. <https://jamanetwork.com/journals/jamaoncology/fullarticle/2772789>
82. **Al-Shamsi, H.O.**, 2020. Rethinking Cancer Screening and Diagnosis During the Covid-19 Pandemic. *Journal of Oncology Research Review & Reports. SRC/JORRR/110*.
83. **Al-Shamsi, H. O.**, et al. 2020. Early Onset Colorectal Cancer in the United Arab Emirates, Where do we Stand?". *Acta Scientific Cancer Biology*, 4, pp.24-27. https://www.researchgate.net/publication/373894419_Early_Onset_Colorectal_Cancer_in_the_United_Arab_Emirates_Where_do_we_Stand_Mini_Review
84. Abdel-Wahab, R., Hassan, M.M., George, B., Carmagnani Pestana, R., Xiao, L., Lacin, S., Yalcin, S., Shalaby, A.S., **Al-Shamsi, H.O.**, Raghav, K. and Wolff, R.A., 2020. Impact of integrating insulin-like growth factor 1 levels into model for end-stage liver disease score

- for survival prediction in hepatocellular carcinoma patients. *Oncology*, 98(12), pp.836-846. <https://doi.org/10.1159/000502482>
85. **Al-Shamsi, H.O.**, Abu-Gheida, I., Rana, S.K., Nijhawan, N., Abdulsamad, A.S., Alrawi, S., Abuhaleeqa, M., Almansoori, T.M., Alkasab, T., Aleassa, E.M. and McManus, M.C., 2020. Challenges for cancer patients returning home during SARS-COV-19 pandemic after medical tourism-a consensus report by the emirates oncology task force. *BMC cancer*, 20(1), p.641. <https://doi.org/10.1186/s12885-020-07115-6>
 86. **Al-Shamsi, H.O.**, Alhazzani, W., Alhurairji, A., Coomes, E.A., Chemaly, R.F., Almuhanha, M., Wolff, R.A., Ibrahim, N.K., Chua, M.L., Hotte, S.J. and Meyers, B.M., 2020. A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group. *The oncologist*, 25(6), pp.e936-e945. <https://doi.org/10.1634/theoncologist.2020-0213>
 87. Iskanderian, R.R., Karmstaji, A., Mohamed, B.K., Alahmed, S., Masri, M.H., Choufani, E., Ahmed, N., **Al-Shamsi, H.O.** and Grobmyer, S.R., 2020. Outcomes and impact of a universal COVID-19 screening protocol for asymptomatic oncology patients. *Gulf J. Oncolog*, 1, pp.7-12. <https://pubmed.ncbi.nlm.nih.gov/33431356/>
 88. Coomes, E.A., **Al-Shamsi, H.O.**, Meyers, B.M., Alhazzani, W., Alhurairji, A., Chemaly, R.F., Almuhanha, M., Wolff, R.A., Ibrahim, N.K., Chua, M.L. and Hotte, S.J., 2020. Evolution of Cancer Care in Response to the COVID-19 Pandemic. *The Oncologist*, 25(9), pp.e1426-e1427. <https://doi.org/10.1634/theoncologist.2020-0451>
 89. **Al-Shamsi HO** et al , Authors Reply: Oncological surgery during COVID-19 pandemic: The need for deep and lasting measures. <https://doi.org/10.1634/theoncologist.2020-0451>
 90. Jain, A., Borad, M.J., Kelley, R.K., Wang, Y., Abdel-Wahab, R., Meric-Bernstam, F., Baggerly, K.A., Kaseb, A.O., **Al-Shamsi, H.O.**, Ahn, D.H. and DeLeon, T., 2018. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. *JCO Precision Oncology*, 2, pp.1-12. <https://doi.org/10.1200/PO.17.00080>
 91. Abdou, E., Pedapenki, R.M., Abouagour, M., Zar, A.R., Dawoud, E., Elshourbagy, D., **Al-Shamsi, H.O.** and Grande, E., 2020. Patient selection and risk factors in the changing treatment landscape of metastatic renal cell carcinoma. *Expert Review of Anticancer Therapy*, 20(10), pp.831-840. <https://pubmed.ncbi.nlm.nih.gov/32930617/>
 92. Coomes, E.A., **Al-Shamsi, H.O.**, Meyers, B.M., Alhazzani, W., Alhurairji, A., Chemaly, R.F., Almuhanha, M., Wolff, R.A., Ibrahim, N.K., Chua, M.L. and Hotte, S.J., 2020. Authors Reply: How to manage febrile neutropenia during the COVID pandemic? In response to," A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic". *The oncologist*. <https://doi.org/10.1634/theoncologist.2020-0329>
 93. Tashkandi, E., Zeeneldin, A., AlAbdulwahab, A., Elemam, O., Elsamany, S., Jastaniah, W., Abdullah, S., Alfayez, M., Jazieh, A.R. and **Al-Shamsi, H.O.**, 2020. Virtual management of patients with cancer during the COVID-19 pandemic: web-based questionnaire study. *Journal of medical Internet research*, 22(6), p.e19691. <https://doi.org/10.2196/19691>

94. Al-Shamsi, H.O. 2020. Mammography screening for breast cancer—the UK Age trial. *The Lancet Oncology*, 21(11), e505. [https://doi.org/10.1016/S1470-2045\(20\)30492-7](https://doi.org/10.1016/S1470-2045(20)30492-7)
95. Al-Shamsi, H.O. 2020. COVID-19 Vaccination for Cancer Patients, What Oncologists and Cancer Patients Need to Know?. *Journal of Oncology. Research Review & Reports. SRC/JONRR-114.*
96. Suhaili, A.R., Mayank Kothari, M., Sadir Alrawi, S., Al-Shamsi, H.O., 2020. Anterior Mediastinal Mass: A Rare Presentation of Thyroid Mass Compressing Mediastinal Structures. *Journal of Oncology. Research Review & Reports. SRC/JONRR-113.* <https://scispace.com/pdf/anterior-mediastinal-mass-a-rare-presentation-of-thyroid-lotij4ifxb.pdf>
97. Abusanad, A.M. and Al-Shamsi, H.O., 2021. Tele-Oncology: An Emerging Technology in Developing Countries during the COVID-19 Pandemic. *New Emirates Medical Journal*, 2(1), pp.13-15. <http://dx.doi.org/10.2174/0250688201999201109160857>
98. Benbrahim, Z., Al Asiri, M., Al Bahrani, B., AlNassar, M.A.M.A., Al-Shamsi, H.O., Bounedjar, A., El Saghir, N., Fahed, Z., Khatib, S., Khorshid, O.M.R., Labidi, S., et al. 2020. 1737P National approaches to managing cancer care: Responses of countries in the MENA region to COVID-19 pandemic. *Annals of Oncology*, 31, p.S1016. <https://doi.org/10.1016/j.annonc.2020.08.1801>
99. Abdulsamad, A.S., Inam, A., Oner, M., Al-Shamsi, H.O., Alrawi, S.J., et al. 2019. Malignant Peritoneal Mesothelioma Following Wilmsâ€™™ Tumor in a Horse-Shoe Kidney, A Case Report and Review of Literature. *Cancer Therapy & Oncology International Journal*, 13(2), pp.66-71. <http://dx.doi.org/10.19080/CTOIJ.2019.13.555859>
100. Al-Shamsi, H.O. and Tareen, M., 2018. Palliative care in the United Arab Emirates, a desperate need. *Palliat Med Care*, 5(3), pp.1-4. <http://dx.doi.org/10.15226/2374-8362/5/3/00161>
101. Al-Shamsi, H.O., Al-Hajeili, M. and Alrawi, S., 2018. Chasing the cure around the globe: medical tourism for cancer care from developing countries. *Journal of global oncology*, 4, pp.JGO-17. <https://pmc.ncbi.nlm.nih.gov/articles/PMC6180774/>
102. Al-Shamsi, H.O., 2018. Expatriates with cancer diagnosis in the United Arab Emirates, hanging on the edge. *J Cancer Prev Curr Res*, 9(5), pp.257-258. <https://eos-uae.com/wp-content/uploads/2020/04/3.-JCPCR-09-00364-1.pdf>
103. Al-Shamsi, H.O. and Alrawi, S., 2018. Breast cancer screening in the United Arab Emirates: is it time to call for a screening at an earlier age. *J Cancer Prev Curr Res*, 9(3), pp.123-126. <https://doi.org/10.15406/jcpcr.2018.09.00334>
104. Al-Shamsi, H.O., Tashkandi, E., Bukhari, N., Al Farsi, A., Alnajjar, A., Alhuraiji, A., Foheidi, M., Sagheir, A., Thani, K.B., Al Bahrani, B. and Alrawi, S., 2018. Awareness, understanding, attitude and barriers toward prescribing modern cancer immunotherapies in the Arabian Gulf countries. *Gulf J Oncolog*, 1, pp.45-51. <https://eos.ae/wp-content/uploads/2020/04/5.-EOS-Awareness-article-2-1.pdf>

105. Bukhari, N., **Al-Shamsi, H.O.** and Azam, F., 2018. Update on the treatment of metastatic urothelial carcinoma. *The Scientific World Journal*, 2018(1), p.5682078. <https://doi.org/10.1155/2018/5682078>
106. Khan, M. and **Al-Shamsi, H.O.**, 2018. Long-Standing Course of Disease in a Patient with Muir-Torre Syndrome. *JOJ Case Stud.* 7(3): 555712. <https://juniperpublishers.com/jojcs/JOJCS.MS.ID.555712.php>
107. Jones, J.C., Renfro, L.A., **Al-Shamsi, H.O.**, Schrock, A.B., Rankin, A., Zhang, B.Y., et al. 2017. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. *Journal of Clinical Oncology*, 35(23), pp.2624-2630. <https://doi.org/10.1200/JCO.2016.71.4394>
108. Meyers, B.M., **Al-Shamsi, H.O.**, Rask, S., Yelamanchili, R., Phillips, C.M., Papaioannou, A., Pond, G.R., Jeyabalan, N., Zbuk, K.M. and Dhesy-Thind, S.K., 2017. Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer. *Journal of gastrointestinal oncology*, 8(1), p.32. <https://doi.org/10.21037/jgo.2016.11.12>
109. **Al-Shamsi, H.O.**, Lau, A.N., Malik, K., Alamri, A., Ioannidis, G., Corbett, T., Adachi, J.D. and Papaioannou, A., 2017. Corrigendum to "The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer". *Journal of Oncology*, 2017, pp.1-1. <https://doi.org/10.1155/2017/3432604>
110. Abdel-Wahab, R., Hassan, M., Wolff, R.A., Lacin, S., **Al-Shamsi, H.O.**, Raghav, K.P.S., Shalaby, A.S., Yao, J.C. and Kaseb, A.O., 2017. Association of elevated alpha-1 antitrypsin with advanced clinicopathologic features of hepatocellular carcinoma. *J Clin Oncol* 35, 289-289. https://doi.org/10.1200/JCO.2017.35.4_suppl.289
111. **Al-Shamsi, H.O.**, Jones, J., Fahmawi, Y., Dahbour, I., Tabash, A., Abdel-Wahab, R., Abousamra, A.O., Shaw, K.R., Xiao, L., Hassan, M.M., Kipp, B.R., et al. 2016. Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern. *Journal of gastrointestinal oncology*, 7(6), p.882. doi: 10.21037/jgo.2016.11.02 <https://jgo.amegroups.org/article/view/10606/9407>
112. **Al-Shamsi, H.O.** and Ibrahim, N.K., 2016. The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better. *Translational Cancer Research*, 5(Suppl 4). doi: 10.21037/tcr.2016.10.82. <https://tcr.amegroups.org/article/view/10131/html>
113. **Al-Shamsi, H.O.**, Fahmawi, Y., Dahbour, I., Tabash, A., Rogers, J.E., Mares, J.E., Blum, M.A., Estrella, J., Matamoros Jr, A., Sagebiel, T., Devine, C.E., et al. 2016. Continuation of trastuzumab beyond disease progression in HER2-positive metastatic gastric cancer: the MD Anderson experience. *Journal of Gastrointestinal Oncology*, 7(4), p.499. <https://doi.org/10.21037/jgo.2016.06.16>

114. **Al-Shamsi, H.O.**, Anand, D., Shroff, R.T., Jain, A., Zuo, M., Conrad, C., Vauthey, J.N. and Javle, M.M., 2016. BRCA-associated protein 1 mutant cholangiocarcinoma: an aggressive disease subtype. *Journal of gastrointestinal oncology*, 7(4), p.556. <https://doi.org/10.21037/jgo.2016.03.05>
115. **Al-Shamsi, H.O.**, Alzahrani, M. and Wolff, R.A., 2016. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer—a report of two cases. *Journal of Gastrointestinal Oncology*, 7(3), p.E45. <https://doi.org/10.21037/jgo.2016.01.05>
116. **Al-Shamsi, H.O.**, Rogers, J., Mares, J.E., Blum, M.A., Dahbour, I., Fahmawi, Y., Lin, Q. and Ajani, J.A., 2016. Continuation of trastuzumab beyond disease progression in patients with metastatic gastric cancer: A retrospective analysis of 25 cases—The MD Anderson experience. *J Clin Oncol* 34, e15560(2016). https://doi.org/10.1200/JCO.2016.34.15_suppl.e15560
117. Kaseb, A.O., Morris, J.S., Iwasaki, M., **Al-Shamsi, H.O.**, Raghav, K.P.S., Girard, L., Cheung, S., Nguyen, V., Elsayes, K.M., Xiao, L., Abdel-Wahab, R., et al. 2016. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. *OncoTargets and therapy*, pp.773-780. <https://doi.org/10.2147/ott.s91977>
118. **Al-Shamsi, H.O.**, Abdel-Wahab, R., Hassan, M., Botrus, G., Shalaby, A.S., Wolff, R.A. and Kaseb, A.O., 2016. Natural history of TINOM0 hepatocellular carcinoma: Large scale study in the United States. *J Clin Oncol* 34, 416-416(2016). https://doi.org/10.1200/jco.2016.34.4_suppl.416
119. **Al-Shamsi, H.O.**, Shalaby, A., Dar, A.Y., Hassan, M., Wolff, R.A. and Li, D., 2016. Prognostic effect of angiotensin-converting-enzyme inhibitors (ACEI) and diuretics in patients with pancreatic cancer. *J Clin Oncol* 34, 420(2016). https://doi.org/10.1200/jco.2016.34.4_suppl.420
120. Kaseb A, Morris J, Iwasaki M, **Al-Shamsi H**, Raghav K, Girard L, Cheung S, Nguyen V, Elsayes K, Xiao L, Abdel-Wahab R, Shalaby A, Hassan M, Hassabo H, Wolff R, Yao J. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. *Onco Targets Ther.* 2016;9:773-780. <https://doi.org/10.2147/OTT.S91977>
121. Kaseb, A.O., **Al-Shamsi, H.O.**, Morris, J., Iwasaki, M., Xiao, L., Abdel-Wahab, R., Raghav, K.P.S., Hassan, M., Hassabo, H.M. and Wolff, R.A., 2015. P-114 A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma. *Annals of Oncology*, 26iv32. <https://doi.org/10.1093/annonc/mdv233.114>
122. **Al-Shamsi, H.O.**, Alhazzani, W. and Wolff, R.A., 2015. Extended RAS testing in metastatic colorectal cancer—Refining the predictive molecular biomarkers. *Journal of gastrointestinal oncology*, 6(3), p.314. <https://doi.org/10.3978/j.issn.2078-6891.2015.016>
123. **Al-Shamsi, H.O.**, Kee, B.K., Tetzlaff, M.T. and Wolff, R.A., 2015. Capecitabine-induced leukocytoclastic vasculitis under neoadjuvant chemotherapy for locally advanced colorectal cancer. *Journal of Gastrointestinal Oncology*, 6(3), p.E40. <https://doi.org/10.3978/j.issn.2078-6891.2015.003>

124. **Al-Shamsi, H.O.**, Al Farsi, A., Anjum, M., Shen, H., Zbuk, K., Cook, R.J., Linkins, L.A. and Major, P., 2015. Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotecan (FOLFIRI) plus bevacizumab. *Journal of gastrointestinal oncology*, 6(3), p.274. <https://doi.org/10.3978/j.issn.2078-6891.2015.025>
125. Alhazzani, W., **Al-Shamsi, H.O.**, Greenwald, E., Radhi, J. and Tse, F., 2015. Chronic abdominal pain secondary to mesenteric panniculitis treated successfully with endoscopic ultrasonography-guided celiac plexus block: a case report. *World Journal of Gastrointestinal Endoscopy*, 7(5), p.563. <https://doi.org/10.4253/wjge.v7.i5.563>
126. Javle, M., Churi, C., Kang, H.C., Shroff, R., Janku, F., Surapaneni, R., Zuo, M., Barrera, C., **Al-Shamsi, H.O.**, Krishnan, S., Mishra, L., et al. 2015. HER2/neu-directed therapy for biliary tract cancer. *Journal of hematology & oncology*, 8(1), p.58. <https://doi.org/10.1186/s13045-015-0155-z>
127. Clayton, R., Wu, J., Heng, D.Y., North, S.A., Emmenegger, U., Hotte, S., Chi, K., Zielinski, R., **Al-Shamsi, H.**, Chen, L. and Eigl, B., 2014. A multicentre analysis of abiraterone acetate in Canadian patients with metastatic castration-resistant prostate cancer. *Canadian Urological Association Journal*, 8(9-10), p.E583. <https://doi.org/10.5489/cuaj.1891>
128. **Al-Shamsi, H.O.**, Al Farsi, A. and Ellis, P.M., 2014. Stage III Non-Small-Cell Lung Cancer: Establishing a Benchmark for the Proportion of Patients Suitable for Radical Treatment. *Clinical Lung Cancer*, 15(4), pp.274-280. <https://doi.org/10.1016/j.clcc.2014.02.003>
129. **Al-Shamsi, H.O.**, Lau, A.N., Malik, K., Alamri, A., Ioannidis, G., Corbett, T., Adachi, J.D. and Papaioannou, A., 2012. The current practice of screening, prevention, and treatment of androgen-deprivation-therapy induced osteoporosis in patients with prostate cancer. *Journal of oncology*, 2012(1), p.958596. <https://doi.org/10.1155/2012/958596>

IN PRESS

1. Book – *Palliative Care in the Arab World (CC BY 4.0)*, by Springer

<https://www.harvard.com/book/9789819606351>

This open-access book explores the growing role of palliative care in the Middle East, reflecting a global shift toward recognizing it as essential to public health and a fundamental right for patients with life-threatening illnesses. The World Health Organization (WHO) defines palliative care as a holistic approach addressing physical, emotional, and spiritual needs, extending beyond treatment to relieve suffering and improve quality of life. Delivered in hospitals, clinics, and homes, it engages families and communities through a multidisciplinary framework.

2. Book – *Cancer Care in Africa (CC BY 4.0)*, by Springer
3. Book – *Cancer in the Arab World (2nd Edition)*, by Springer

ABSTRACTS

American Society of Clinical Oncology – ASCO 2015 meeting

1. Abstract Number e1513. **Al-Shamsi, H.O.**, Barrera, C.D., Surapaneni, R., Kang, H., Shroff, R.T., Janku, F., Krishnan, S., Zuo, M., Wolff, R.A., Kaseb, A.O. and Thomas, M.B., 2015. HER2/neu-directed therapy for biliary tract cancer. https://doi.org/10.1200/jco.2015.33.15_suppl.e15137
2. Kaseb, A.O., Al-Shamsi, H.O., Morris, J., Iwasaki, M., Xiao, L., Abdel-Wahab, R., Raghav, K.P.S., Hassan, M., Hassabo, H.M. and Wolff, R.A., 2015. A phase II trial of bevacizumab and erlotinib as second line therapy for advanced hepatocellular carcinoma. *J Clin Oncol* 33, 4088-4088(2015). https://doi.org/10.1200/jco.2015.33.15_suppl.4088
3. Meyers, B.M., Al-Shamsi, H.O., and Figueredo, A.T., 2015. Cochrane systematic review and meta-analysis of adjuvant therapy for stage II colon cancer. *J Clin Oncol* 33, 3513-3513. https://doi.org/10.1200/jco.2015.33.15_suppl.3513
4. **Al-Shamsi, H.O.**, Abdel-Wahab, R., Hassan, M., Botrus, G., Shalaby, A.S., Wolff, R.A. et al. 2015. Natural History of TINOM0 Hepatocellular carcinoma: Large scale study in the United States. *Oncology*, 93(4), 233-242. https://doi.org/10.1200/jco.2015.33.15_suppl.e15120

American Society of Clinical Oncology – ASCO 2013 meeting

1. Dhesy-Thind, S.K., Meyers, B.M., **Al-Shamsi, H.O.**, Papaioannou, A., Zbuk, K.M. and Pond, G.R., 2013. Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients. *J Clin Oncol* 31, e20522-e20522. https://doi.org/10.1200/jco.2013.31.15_suppl.e20522
2. **Al-Shamsi, H.O.**, Anjum, M., Al Farsi, A.M., Shen, H., Cook, R.J., Linkins, L.A. and Major, P., 2013. Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab. *J Clin Oncol* 31, e14630-e14630. https://doi.org/10.1200/jco.2013.31.15_suppl.e14630
3. Clayton, R., Heng, D.Y.C., Wu, J.S., Zielinski, R., North, S.A., Emmenegger, U., Hotte, S.J., **Al-Shamsi, H.O.**, Chen, L. and Eigel, B.J., 2013. A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC). *J Clin Oncol* 31, 113-113. https://doi.org/10.1200/jco.2013.31.6_suppl.113

Gastrointestinal Cancers Symposium - American Society of Clinical Oncology – ASCO 2013 meeting

1. *J Clin Oncol* 30: 2012 (suppl 34; abstr 540), Venous thromboembolism events in patients with Colorectal Cancer treated with FOLFIRI Plus bevacizumab - JCC Regional cancer centre Experience, **Humaid Al-Shamsi MD, FRCPC**, Major, P MD

American Society of Clinical Oncology – ASCO 2012 meeting

1. Al-Shamsi, H.O. and Ellis, P.M., 2012. Stage III NSCLC: How many patients are really suitable for radical treatment approaches?. *J Clin Oncol* 30, e17532-e17532. Supervisor Dr.P.Ellis. https://doi.org/10.1200/jco.2012.30.15_suppl.e17532
2. Meyers, B.M., Yelamanchili, R., Rask, S., **Al-Shamsi, H.O.**, Phillips, C.M., Papaioannou, A., Zbuk, K.M., Gu, C.S., Jeyabalan, N. and Dhesy-Thind, S.K., 2012. Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC). *J Clin Oncol* 30, e14001-e14001. https://doi.org/10.1200/jco.2012.30.15_suppl.e14001

Genitourinary Cancers Symposium - American Society of Clinical Oncology – ASCO 2013 meeting

1. Clayton, R., Heng, D.Y.C., Wu, J.S., Zielinski, R., North, S.A., Emmenegger, U., Hotte, S.J., **Al-Shamsi, H.O.**, Chen, L. and Eigl, B.J., 2013. A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC). *J Clin Oncol* 31, 113-113. https://doi.org/10.1200/jco.2013.31.6_suppl.113
1. Urban Emmenegger MD4, Sebastian Hotte MD, FRCPC5, Rob Zielinski MD2, **Humaid Al-Shamsi MD5**, Leo Chen2, Bernhard Eigl MD, FRCPC2. General Poster Session A: colon Cancer Abstract ID: 2382

American Society for Radiation Oncology (ASTRO) 2012 meeting

1. Clayton, R., Wu, J., Heng, D.Y., North, S.A., Emmenegger, U., Al-Shamsi, H.O., Hotte, S.J. and Eigl, B.J., 2012. Utilization of Radiation Therapy in Metastatic Castration Resistant Prostate Cancer Following the Introduction of Abiraterone into Clinical Oncology Practice. *International Journal of Radiation Oncology, Biology, Physics*, 84(3), pp.S361-S362. <https://doi.org/10.1016/j.ijrobp.2012.07.954>
2. Urban Emmenegger MD4, Sebastian Hotte MD, FRCPC5, Rob Zielinski MD2, **Humaid Al-Shamsi MD5**, Leo Chen2, Bernhard Eigl MD, FRCPC2. General Poster Session A: Prostate Cancer, Abstract ID: 113

Canadian Association of Medical Oncologists – CAMO meeting 2012

1. Stage III NSCLC: How many patients are really suitable for radical treatment approaches? **Humaid Al-Shamsi**, Dr.P.Ellis
2. Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC). Brandon M Meyers, Radhika Yelamanchili, Sara Rask, **Humaid Al-Shamsi**, Callista Maria Phillips, Alexandra Papaioannou, Kevin M. Zbuk, Chu Shu Gu, Neera Jeyabalan, Sukhbinder K. Dhesy-Thind. *Clinical Journal of Oncology* 2012.
3. The Current practice of screening, prevention and treatment of Androgen Deprivation Therapy (ADT) induced Osteoporosis in patients with Prostate Cancer. **Alshamsi, Humaid**, A.Papaioannou

Ontario Thoracic Cancer Conference 2012

1. *Stage III NSCLC: How many patients are really suitable for radical treatment approaches?*
Supervisor Dr.P.Ellis

Canadian society of internal medicine- Vancouver, BC Oct 2010

1. *The Current practice of screening, prevention and treatment of Androgen Deprivation Therapy (ADT) induced Osteoporosis in patients with Prostate Cancer.* **Alshamsi, Humaid, A.Papaoiannou**

ASCO Commentary

1. *Training Tomorrow's Oncologists at Home: Establishing the UAE's First Hematology-Oncology Fellowship Training Program (April 2026).* <https://connection.asco.org/do/training-tomorrow-s-oncologists-home-establishing-uae-s-first-hematology-oncology>

2. *Establishing and Launching a Comprehensive Bone Marrow Transplant Unit in the UAE Amidst the COVID-19 Pandemic: Overcoming Barriers Through International Collaboration and Resilience.* **Humaid O. Al Shamsi** (December 2021). <https://connection.asco.org/do/establishing-and-launching-comprehensive-bone-marrow-transplant-unit-uae-amidst-covid>

ASCO Post

1. *Cancer in the Arab World: Addressing Challenges to Improve Outcomes.* **Humaid O. Al Shamsi** (March 2022). <https://ascopost.com/issues/march-10-2022/cancer-in-the-arab-world-addressing-challenges-to-improve-outcomes/>

TEACHING & ACADEMIC ACTIVITIES

- **Clinical supervisors for internal medicine residents during their rotation in the oncology department at Tawam Hospital, Al Ain, UAE.**
Jul 2017 – Current
- **Clinical supervisors for fellows and residents during their rotation in the oncology department at MD Anderson cancer center.**
Jun 2014 – Jan 2017
- **Planner and organizer of the medical oncology journal club at McMaster University**
Jul 2012 - Jun 2013
- **McMaster Undergraduate MD program OSCE – Examiner**
Nov 2007 and Jun 2008
Precipitated in OSCE Examination for MD program as an examiner to gain experience and improve Feedback skills.
- **ECG Crash Course for Junior residents and Medical Students**
Dec 2008 and Apr 2009
Prepared 6 hours' workshop training for Junior residents and medical students during CTU covering major aspects of ECG interpretation with excellent feedback from learners.

COMMUNITY ACTIVITIES

- Sharjah Morning program interview, World Cancer Day, explained to the public in simple language the importance of early cancer screening. <https://www.youtube.com/watch?v=xE3KEyJpygs>
- Friends of cancer event – Early cancer screening – a talk targeted to the general public audience titled “Early cancer detection, When and How?” 20-Jan-2018.
- Free medical consultation for Cancer patient at Al Zahra Hospital – Dubai Jul 2017 - Present

LECTURES & WORKSHOPS

Presented University of Sharjah in more than 50 presentations over the Mar 2017-Mar 2020 – only few listed here

- **Combined Chemo-immunotherapy in NSCLC is it ready for the prime time? Clinical Case Discussion**, Immuno-Oncology Summit, Dubai, UAE, December 15, 2019
- **SP147 assay PDL-1 interpretation in clinical practice (NSCLC and GU cancers) - PDL-1 workshop for pathologist from the gulf region (KSA, Iraq, UAE)**, Dubai, December 16, 2019
- **Colorectal and breast cancer guidelines workshop – The gulf federation for cancer control**, Member of the gulf federation for cancer control taskforce for colorectal and breast cancer guidelines, Kuwait City, Kuwait, Nov 26-27, 2018
- **The role of bevacizumab in advanced colorectal cancer**, Journal club, Dubai, UAE, Nov 20, 2019
- **Defining the Genomic Landscape of Colorectal Cancer**, Emirates Oncology Conference, Abu Dhabi, Nov 17, 2019
- **Update in the management of advanced colorectal cancer in the second line setting**, Oman Cancer conference, Muscat, Oman, Oct 12, 2018
- **Defining the Genomic Landscape of Colorectal Cancer**, UAE Cancer congress, Dubai, UAE, Oct 6, 2017
- **Advances in the management of metastatic castrate resistant prostate cancer**, UAE Cancer congress, Dubai, UAE, Oct 6, 2019

ADVISORY BOARD

- **3rd Gulf Breast Cancer Advisory Board**, Pfizar, Abu Dhabi, UAE, 18-Nov-2019
- **Biosimilar advisory board**, Pfizar, Dubai, UAE, 11-Nov-2019

- **Hepatocellular carcinoma treatment advisory board**, Bristol-Myers Squibb, Dubai, UAE, 04-Nov-2019

MENTORSHIP

Providing ongoing support to junior UAE physicians:

- Dr. Aydah Alawadi, Mentorship throughout internal medicine training and support to gain fellowship training at MD Anderson Cancer Center, Houston, Texas, USA. Due to complete Medical Oncology fellowship training in June 2019 and planning to do Breast Fellowship at MD Anderson Cancer
- Dr. Zaki Ajlan, Mentorship throughout medical school training, one to one advice and support regarding how to choose subspecialty for postgraduate training. Dr. Ajlan was matched to Stanford University internal medicine program, Stanford, California, USA in March 2018 with guaranteed medical oncology fellowship upon the completion of the internal medicine residency program.

AFFILIATIONS

- Member, Emirates Oncology Associations, 2017 -Present
- Member, The International Society of Gastrointestinal Oncology (ISGIO), Jan 2014 - Present
- Member, American Society of Clinical Oncology (ASCO), Nov 2013 - Present
- Member, The European Society for Medical Oncology (ESMO), Nov 2013 - Present
- Fellow of the Royal College of Physician and Surgeon of Canada, Jul 2011 - Present
- Fellow of the American College of Physicians 2007 - Present
- Member, The Canadian Medical Protective Association 2007 - Present
- Member, UAE Medical Association, 2006 - Present